Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma
Status:
Completed
Trial end date:
2020-09-29
Target enrollment:
Participant gender:
Summary
PRIMARY STUDY OBJECTIVES
- To evaluate the efficacy of the combination of clarithromycin (Biaxin®), lenalidomide
(Revlimid™), and dexamethasone (Decadron®) as an induction therapy for patients with
newly diagnosed multiple myeloma (MM).
- To evaluate the safety of the combination of clarithromycin, lenalidomide, and
dexamethasone as an induction therapy for patients with newly diagnosed MM.
SECONDARY STUDY OBJECTIVES
- To examine the role of clarithromycin on the pharmacokinetic properties of dexamethasone
and lenalidomide.
- To examine the angiogenesis profile in untreated patients and in patients receiving
induction therapy.